Aspects of innate immunity in Sjögren's syndrome

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Low, Hui Z ^a   Witte, Torsten ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIGEN; B CELL ACTIVATING FACTOR; INTERFERON; INTERFERON REGULATORY FACTOR 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAT4 PROTEIN; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTATION; CELL ACTIVATION; CYTOKINE PRODUCTION; DNA POLYMORPHISM; EPITHELIUM CELL; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; INNATE IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MONONUCLEAR CELL; SALIVARY GLAND; SIGNAL TRANSDUCTION;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

EID: 80052224962     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3318     Document Type: Review

References (48)

1. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002, 22:5721-5740. 10.1128/MCB.22.16.5721-5740.2002, 133975, 12138184.
2. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A, Honda K, Taniguchi T. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 2007, 104:3402-3407. 10.1073/pnas.0611559104, 1805533, 17360658.
3. Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X. Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis Rheum 2007, 56:3989-3994. 10.1002/art.23142, 18050197.
4. Nordmark G, Kristjansdottir G, Theander E, Eriksson P, Brun JG, Wang C, Padyukov L, Truedsson L, Alm G, Eloranta ML, Jonsson R, Rönnblom L, Syvänen AC. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes Immun 2009, 10:68-76. 10.1038/gene.2008.94, 19092842.
5. Miceli-Richard C, Gestermann N, Ittah M, Comets E, Loiseau P, Puechal X, Hachulla E, Gottenberg JE, Lebon P, Becquemont L, Mariette X. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. Arthritis Rheum 2009, 60:1991-1997. 10.1002/art.24662, 19565491.
6. Sigurdsson S, Goring HHH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, Eloranta M-L, Feng D, Sangster-Guity N, Gunnarsson I, Svenungsson E, Sturfelt G, Jonsen A, Truedsson L, Barnes BJ, Alm G, Ronnblom L, Syvanen A-C. Comprehensive evaluation of the genetic variants of interferon regulatory growth factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008, 17:872-881.
7. Sigurdsson S, Nordmark G, Goring HHH, Lindroos K, Wiman A-C, Sturfelt G, Jonsen A, Rantapaa-Dahlqvist S, Moller B, Kere J, Koskenmies S, Widen E, Eloranta M-L, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Ronnblom L, Syvanen A-C. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005, 76:528-537. 10.1086/428480, 1196404, 15657875.
8. Sigurdsson S, Padyukov L, Kurreeman FAS, Liljedahl U, Wiman A-C, Alfredsson L, Toes R, Ronnelid J, Klareskog L, Huizinga TWJ, Alm G, Syvanen A-C, Ronnblom L. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007, 56:2202-2210. 10.1002/art.22704, 17599733.
9. Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, Wiman A-C, Vermeire S, Rutgeerts P, Belaiche J, Franchimont D, Van Gossum A, Bours V, Syvanen A-C. An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 2007, 16:3008-3016. 10.1093/hmg/ddm259, 17881657.
10. Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S, Centola M, Wu C-Y, Yamada N, Gabalaway HE, O'Shea JJ. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol 2000, 164:4659-4664.
11. Korman BD, Alba MI, Le JM, Alevizos I, Smith JA, Nikolov NP, Kastner DL, Remmers EF, Illei GG. Variant form of STAT4 is associated with primary Sjögren's syndrome. Genes Immun 2008, 9:267-270. 10.1038/gene.2008.1, 18273036.
12. Palomino-Morales RJ, Diaz-Gallo LM, Witte T, Anaya JM, Martín J. Influence of STAT4 polymorphism in primary Sjögren's syndrome. J Rheumatol 2010, 37:1016-1019. 10.3899/jrheum.091007, 20360187.
13. Gestermann N, Mekinian A, Comets E, Loiseau P, Puechal X, Hachulla E, Gottenberg JE, Mariette X, Miceli-Richard C. STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun 2010, 11:432-438. 10.1038/gene.2010.29, 20535138.
14. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986. 10.1056/NEJMoa073003, 2630215, 17804842.
15. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jönsen A, Bengtsson AA, Rantapää-Dahlqvist S, Baechler EC, Brown EE, Alarcón GS, Edberg JC, Ramsey-Goldman R, McGwin G, Reveille JD, Vilá LM, Kimberly RP, Manzi S, Petri MA, Lee A, Gregersen PK, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009, 41:1228-1233. 10.1038/ng.468, 2925843, 19838195.
16. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, Xu JH, Cai ZM, Huang W, Zhao GP, Xie HF, Fang H, Lu QJ, Xu JH, Li XP, Pan YF, Deng DQ, Zeng FQ, Ye ZZ, Zhang XY, Wang QW, Hao F, Ma L, Zuo XB, Zhou FS, Du WH, Cheng YL, Yang JQ, Shen SK, Li J, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009, 41:1234-1237. 10.1038/ng.472, 19838193.
17. Martínez A, Varadé J, Márquez A, Cénit MC, Espino L, Perdigones N, Santiago JL, Fernández-Arquero M, de la Calle H, Arroyo R, Mendoza JL, Fernández-Gutiérrez B, de la Concha EG, Urcelay E. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum 2008, 58:2598-2602. 10.1002/art.23792, 18759272.
18. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Suárez H, Ortego-Centeno N, Riemekasten G, Fonollosa V, Vonk MC, van den Hoogen FH, Sanchez-Román J, Aguirre-Zamorano MA, García-Portales R, Pros A, Camps MT, Gonzalez-Gay MA, Coenen MJ, Airo P, Beretta L, Scorza R, van Laar J, Gonzalez-Escribano MF, Nelson JL, Radstake TR, Martin J. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009, 18:2071-2077. 10.1093/hmg/ddp119, 19286670.
19. Abelson AK, Delgado-Vega AM, Kozyrev SV, Sánchez E, Velázquez-Cruz R, Eriksson N, Wojcik J, Linga Reddy MV, Lima G, D'Alfonso S, Migliaresi S, Baca V, Orozco L, Witte T, Ortego-Centeno N, , Abderrahim H, Pons-Estel BA, Gutiérrez C, Suárez A, González-Escribano MF, Martin J, Alarcón-Riquelme ME. AADEA group STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009, 68:1746-1753. 10.1136/ard.2008.097642, 19019891, AADEA group.
20. Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008, 17:2868-2876. 10.1093/hmg/ddn184, 2525501, 18579578.
21. Höss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J 1999, 18:3868-3875. 10.1093/emboj/18.13.3868, 1171463, 10393201.
22. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, Black DN, van Bokhoven H, Brunner HG, Hamel BC, Corry PC, Cowan FM, Frints SG, Klepper J, Livingston JH, Lynch SA, Massey RF, Meritet JF, Michaud JL, Ponsot G, Voit T, Lebon P, Bonthron DT, Jackson AP, Barnes DE, Lindahl T. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet 2006, 38:917-920. 10.1038/ng1845, 16845398.
23. Lee-Kirsch MA, Chowdhury D, Harvey S, Gong M, Senenko L, Engel K, Pfeiffer C, Hollis T, Gahr M, Perrino FW, Lieberman J, Hubner N. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med 2007, 85:531-537. 10.1007/s00109-007-0199-9, 17440703.
24. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, de Silva U, Bailey SL, Witte T, Vyse TJ, Kere J, Pfeiffer C, Harvey S, Wong A, Koskenmies S, Hummel O, Rohde K, Schmidt RE, Dominiczak AF, Gahr M, Hollis T, Perrino FW, Lieberman J, Hübner N. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007, 39:1065-1067. 10.1038/ng2091, 17660818.
25. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598. 10.1016/j.cell.2008.06.032, 2626626, 18724932.
26. Morita M, Stamp G, Robins P, Dulic A, Rosewell I, Hrivnak G, Daly G, Lindahl T, Barnes DE. Gene-targeted mice lacking the Trex1 (DNase III) 3'→5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004, 24:6719-6727. 10.1128/MCB.24.15.6719-6727.2004, 444847, 15254239.
27. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005, 52:1534-1544. 10.1002/art.21006, 15880807.
28. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA 2006, 103:2770-2775. 10.1073/pnas.0510837103, 1413808, 16477017.
29. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, Segal B, Rhodus NL, Moser KL. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009, 10:285-296. 10.1038/gene.2009.20, 19404300.
30. Båve U, Nordmark G, Lövgren T, Rönnelid J, Cajander S, Eloranta ML, Alm GV, Rönnblom L. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005, 52:1185-1195. 10.1002/art.20998, 15818675.
31. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007, 56:3995-4004. 10.1002/art.23062, 2737264, 18050196.
32. Manoussakis MN, Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Baillieres Best Pract Res Clin Rheumatol 2000, 14:73-95. 10.1053/berh.1999.0078, 10882215.
33. Skopouli FN, Moutsopoulos HM. Autoimmune epithelitis: Sjögren's syndrome. Clin Exp Rheumatol 1994, 12(Suppl 11):S9-11.
34. Yannopoulos DI, Roncin S, Lamour A, Pennec YL, Moutsopoulos HM, Youinou P. Conjunctival epithelial cells from patients with Sjögren's syndrome inappropriately express major histocompatibility complex molecules, La (SS-B) antigen, and heat-shock proteins. J Clin Immunol 1992, 12:259-265. 10.1007/BF00918149, 1512299.
35. Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009, 38:42-47. 2763314, 19192049.
36. Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. Arthritis Rheum 2005, 52:1517-1521. 10.1002/art.21005, 15880835.
37. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305. 10.1126/science.1071059, 11951032.
38. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005, 17:359-365. 10.1016/j.coi.2005.06.002, 15955682.
39. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606. 10.1038/35079114, 11385577.
40. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603. 10.1038/35079107, 11385576.
41. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, Chamaillard M, Zouali H, Thomas G, Hugot JP. CARD15 mutations in Blau syndrome. Nat Genet 2001, 29:19-20. 10.1038/ng720, 11528384.
42. Spachidou MP, Bourazopoulou E, Maratheftis CI, Kapsogeorgou EK, Moutsopoulos HM, Tzioufas AG, Manoussakis MN. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin Exp Immunol 2007, 147:497-503. 10.1111/j.1365-2249.2006.03311.x, 1810489, 17302899.
43. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68. 150825, 11781351.
44. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003, 62:168-171. 10.1136/ard.62.2.168, 1754442, 12525388.
45. Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A, Youinou P, Pers JO. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007, 56:1134-1144. 10.1002/art.22458, 17393395.
46. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum 2004, 50:2897-2902. 10.1002/art.20463, 15457458.
47. Arakaki R, Nagaoka A, Ishimaru N, Yamada A, Yoshida S, Hayashi Y. Role of plasmacytoid dendritic cells for aberrant class II expression in exocrine glands from estrogen-deficient mice of healthy background. Am J Pathol 2009, 174:1715-1724. 10.2353/ajpath.2009.080695, 2671260, 19359524.
48. Ishimaru N, Arakaki R, Yoshida S, Yamada A, Noji S, Hayashi Y. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy. J Exp Med 2008, 205:2915-2927. 10.1084/jem.20080174, 2585852, 19015307.